Exosome therapy for hair loss is an emerging investigational treatment attracting growing interest in the UK. Exosomes are tiny vesicles released by cells that carry proteins and genetic material, and preparations derived from mesenchymal stem cells are being explored for their potential to support hair follicle activity. However, no exosome product is currently licensed by the MHRA for alopecia, and the evidence base remains at an early stage. This article explains how exosome therapy works, what the current research shows, the UK regulatory position, who might be suitable, and how to access treatment safely and lawfully.

What Is Exosome Therapy and How Does It Work for Hair Loss?

Exosome therapy uses cell-derived vesicles carrying proteins and RNA, administered via scalp injection, to potentially stimulate hair follicle activity — though proposed mechanisms remain largely unproven in robust human trials.

Exosomes are tiny extracellular vesicles — naturally occurring structures released by cells — that carry proteins, lipids, and genetic material such as messenger RNA and microRNA. They act as intercellular messengers, facilitating communication between cells and influencing a wide range of biological processes, including tissue repair. In the context of hair loss, exosomes derived from mesenchymal stem cells (MSCs) — sourced from adipose tissue, bone marrow, or umbilical cord, among other origins — are of particular research interest.

Not sure if this is normal? Chat with one of our pharmacists →

Several biological mechanisms have been proposed, based largely on preclinical (in vitro and animal) studies, by which exosomes might support hair follicle activity. These hypothetical mechanisms include:

• Stimulation of dermal papilla cells, which are critical regulators of the hair growth cycle

• Promotion of angiogenesis, potentially improving blood supply to hair follicles

• Reduction of local inflammation, which is implicated in conditions such as androgenetic alopecia and alopecia areata

• Activation of growth factor signalling pathways, including Wnt/β-catenin, which plays a role in follicle cycling

It is important to note that these mechanisms have not been conclusively demonstrated in robust human clinical trials. They remain largely hypothetical in the human context and should not be interpreted as established evidence of efficacy.

In clinical application, exosome preparations are typically administered via intradermal injection or microneedling into the scalp. Unlike platelet-rich plasma (PRP), which uses the patient's own blood-derived growth factors, exosome preparations are generally derived from donor cell lines and manufactured as off-the-shelf products. However, sources, processing methods, concentration, and purity vary considerably between manufacturers, which limits the comparability of different products and study findings.

In the UK, exosome products intended to treat hair loss are regulated as medicinal products — specifically as biological medicinal products — rather than as medical devices. They are not typically classified as Advanced Therapy Medicinal Products (ATMPs), which require gene therapy or cell/tissue components meeting specific definitions. No exosome product is currently licensed for the treatment of alopecia in the UK.

What Does the Current Evidence Say About Exosome Treatments?

Evidence is limited to small pilot studies and animal models; no high-quality long-term RCTs exist, and exosome therapy should currently be considered investigational rather than a proven treatment.

The evidence base for exosome therapy in hair loss is still at an early stage. Most published data derive from small-scale pilot studies, in vitro (laboratory) research, and animal models, with only a limited number of human clinical trials completed to date. While early findings are broadly encouraging, the overall quality and volume of evidence does not yet meet the threshold required for established clinical guidelines from bodies such as NICE or the British Association of Dermatologists (BAD).

Several small human studies have reported improvements in hair density, follicle count, and patient-reported outcomes following exosome scalp injections, particularly in individuals with androgenetic alopecia. One randomised controlled pilot study published in the Journal of Cosmetic Dermatology (2023) reported statistically significant increases in hair count and thickness compared to placebo at 12 weeks. However, this and similar studies are limited by small sample sizes, short follow-up periods (outcomes at 12 weeks may not be sustained), and considerable variability in exosome preparation methods, making it difficult to draw firm or generalisable conclusions. Full bibliographic details and trial registration information should be sought before citing such studies in clinical decision-making.

There are currently no high-quality, long-term randomised controlled trials, and no systematic review has yet established a reliable evidence base for routine clinical use. Comparisons with established treatments are also limited. Licensed therapies for hair loss in the UK — including topical minoxidil and oral finasteride (for men) — have robust long-term evidence supporting their efficacy and safety profiles. Other options, such as dutasteride (used off-label) and PRP, may also be discussed in specialist settings, though their licensing status differs. Exosome therapy, by contrast, lacks equivalent longitudinal data.

It is therefore important that patients and clinicians approach claims of efficacy with appropriate caution. Ongoing research, including larger randomised controlled trials with longer follow-up, is needed before exosome therapy can be recommended as a standard treatment option. At present, it should be considered an investigational intervention rather than a proven therapy.

Safety Considerations and the UK Regulatory Position

Exosome therapy is generally well tolerated short-term, but no MHRA-licensed product exists for alopecia in the UK, and any use outside an authorised clinical trial may be unlawful.

From a safety perspective, exosome therapy is generally reported as well tolerated in published studies, with adverse effects typically limited to mild, transient reactions at the injection site, such as redness, swelling, or discomfort. However, because the therapy is still investigational, the full safety profile — particularly with regard to long-term use — has not been comprehensively established.

Experiencing these side effects? Our pharmacists can help you navigate them →

Additional safety concerns that have been identified in the scientific literature include:

• Lack of standardisation: Exosome preparations vary widely between manufacturers in terms of source cells, concentration, purity, and processing methods

• Sterility and endotoxin risks: Without robust manufacturing controls, there is potential for microbial contamination, pyrogen contamination, or adventitious agent transmission

• Donor and material screening: The adequacy of donor screening and quality testing varies and may not meet pharmaceutical standards outside of authorised trials

• Immunogenicity and hypersensitivity: Granulomatous or hypersensitivity reactions are theoretically possible, though rarely reported to date

• Unknown long-term effects: The consequences of repeated exosome administration over months or years remain unclear, including any theoretical effects on cell proliferation

• Unregulated providers: Some clinics may offer exosome treatments outside of a clinical trial or without appropriate authorisation

UK regulatory position

In the UK, exosome products intended to treat hair loss are regulated as biological medicinal products by the Medicines and Healthcare products Regulatory Agency (MHRA). They are not typically classified as Advanced Therapy Medicinal Products (ATMPs) — a category that applies specifically to gene therapy, somatic cell therapy, and tissue-engineered products meeting defined criteria — unless the product meets those specific definitions. Classification is determined on a case-by-case basis by the MHRA.

For routine clinical use, a UK Marketing Authorisation (UKMA) is required. For use within a clinical trial, both an MHRA Clinical Trial Authorisation (CTA) and approval from a Research Ethics Committee (REC) and the Health Research Authority (HRA) are required. There are currently no MHRA-licensed exosome products for the treatment of alopecia in the UK. Any exosome product offered outside an authorised clinical trial framework may therefore be supplied unlawfully.

Patients are strongly advised to:

• Verify that any provider is operating within an MHRA-authorised clinical trial (with a valid CTA and REC/HRA approval)

• Check that the treating clinician is registered with the General Medical Council (GMC) or relevant professional regulator

• Check that the clinic is registered with the Care Quality Commission (CQC) where applicable

• Avoid imported or unverified exosome products of unknown provenance

• Report any suspected adverse effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), which accepts reports for unlicensed as well as licensed medicines

Consulting a GP or NHS consultant dermatologist before proceeding is strongly recommended.

Who May Be Suitable for Exosome Therapy?

Access should only be considered within an MHRA-authorised clinical trial; early studies have focused on androgenetic alopecia, and several groups — including children, pregnant women, and immunocompromised individuals — are not appropriate candidates.

Given the investigational nature of exosome therapy and the absence of any licensed product in the UK, access should only be considered within the context of an MHRA-authorised clinical trial. There are currently no UK clinical guidelines from NICE or the BAD that endorse exosome therapy for any form of alopecia, and no formally defined patient selection criteria exist outside of research protocols.

Based on the available literature, early trials have most commonly enrolled individuals with:

• Androgenetic alopecia (male or female pattern hair loss), the most prevalent form of hair loss

• Alopecia areata, an autoimmune condition causing patchy hair loss — though evidence in this group is very limited and the treatment is not recommended in current UK guidelines

Individuals who have not responded adequately to first-line licensed treatments — such as topical minoxidil or oral finasteride (for men) — may be among those who seek out emerging options. However, any such decision must be made in consultation with a GMC-registered consultant dermatologist with expertise in hair disorders. Patients should be counselled honestly about the current limitations of the evidence and the experimental nature of the treatment.

Red flags requiring prompt dermatology referral

The following features should prompt urgent or expedited referral to a consultant dermatologist and would generally preclude consideration of exosome therapy:

• Scalp pain, tenderness, erythema, scaling, or pustules

• Rapid or extensive hair loss

• Signs of scarring alopecia (e.g., lichen planopilaris, central centrifugal cicatricial alopecia) — these require specialist diagnosis and management; exosome therapy is not appropriate

• Loss of eyebrows or eyelashes

• Features suggestive of tinea capitis

Populations for whom exosome therapy is generally not appropriate:

• Children and adolescents (no safety or efficacy data)

• Pregnancy or breastfeeding (absence of safety data)

• Immunocompromised individuals (unpredictable biological effects)

• Individuals with a history of malignancy or receiving cancer treatment

• Active scalp infections or inflammatory skin conditions at the treatment site

• Individuals with a history of keloid scarring

• Telogen effluvium (a self-limiting condition that typically resolves with identification and management of the underlying cause)

A thorough medical history, scalp examination, and — where indicated — trichoscopy or scalp biopsy should precede any consideration of exosome therapy. Baseline investigations (such as ferritin, full blood count, TSH, and vitamin D or B12 where clinically appropriate) should be performed to exclude treatable underlying causes of hair loss, in line with NICE CKS guidance on androgenetic alopecia and alopecia areata.

Accessing Exosome Therapy in the UK: What to Consider

Exosome therapy is not available on the NHS and is not NICE-recommended; patients should search NIHR Be Part of Research or ISRCTN for authorised trials and consult their GP before pursuing any investigational treatment.

Exosome therapy for hair loss is not available on the NHS and is not recommended within any NICE clinical guideline for alopecia. As no exosome product is currently licensed for hair loss in the UK, lawful access should only be via participation in an MHRA-authorised clinical trial. Private clinics offering exosome treatments outside of such a framework may be doing so unlawfully, and patients should exercise considerable caution.

Finding a legitimate clinical trial

Patients wishing to explore participation in a clinical trial can search the following registries:

• NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) — the primary UK public-facing portal for finding NHS and NIHR-supported trials

• ISRCTN registry (isrctn.com) — a recognised international trial registry including UK studies

• ClinicalTrials.gov — a broader international registry that includes UK-based trials

When evaluating any provider or trial, consider the following:

• Practitioner registration: Treatment should be administered by a clinician registered with the GMC (or relevant professional regulator); verify registration at the GMC online register (gmcuk.org)

• Clinic registration: Check whether the provider is registered with the Care Quality Commission (CQC) for regulated activities (cqc.org.uk — 'Check a provider')

• Trial authorisation: Ask for evidence of a valid MHRA Clinical Trial Authorisation (CTA) number and REC/HRA approval; a reputable trial site will provide this information

• Informed consent: A reputable provider will offer a thorough consultation, explain the investigational nature of the treatment, and provide written information about risks, alternatives, and the right to withdraw

• Realistic expectations: Be cautious of providers making unsubstantiated claims about guaranteed results or superiority over licensed treatments

The cost of exosome therapy in the UK, where offered privately, typically ranges from several hundred to over a thousand pounds per session, and multiple sessions are often recommended. Given the uncertain evidence base and the absence of a licensed product, patients should weigh this financial commitment carefully against the availability of licensed, evidence-based alternatives.

First steps if you are experiencing hair loss

The most appropriate first step is to consult your GP, who can assess for underlying causes — such as thyroid dysfunction, iron deficiency, or hormonal imbalance — and refer you to an NHS or private consultant dermatologist if needed. First-line licensed options, including topical minoxidil and oral finasteride (for men), should be considered and discussed before exploring investigational treatments. The NHS hair loss page, NICE CKS guidance, and BAD patient information are reliable sources of further information.

If you experience any unexpected side effects following any hair loss treatment — licensed or otherwise — please report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions